Scientists at Indiana University were combining ultrasound physics and medical engineering to precisely ablate targeted tissue. The result was the birth of HIFU or high intensity focused ultrasound. 

A small team was established in conjunction with Indiana University School of Medicine, and in 1998 that team formed Focus Surgery, Inc. Complete with a HIFU laboratory, a handful of patents and a number of government grants, the team developed the capacity to manufacture the first Sonablate® system for prostate HIFU ablation.

USHIFU, LLC was established in Charlotte, NC to implement a clinical trial with an early version of the Sonablate® product.

USHIFU, LLC purchased Focus Surgery and a new subsidiary, International HIFU, was created to expand the use and sales of Sonablate® 500 globally.

SonaCare Medical, LLC was established to unify all previously described organizations.

Sonablate became the first focused ultrasound device to be FDA cleared in the US for the ablation of prostate tissue.

As part of an investment, SonaCare Medical merged into a new company to be called Sonablate Corp.

We are a global leader in HIFU therapies with over 30,000 patient procedures completed and regulatory clearance in more than 50 countries.  We are the industry leader in focal therapy with a multitude of publications documenting positive patient outcomes spanning more than a decade.

The best is yet to come.